Targeted Oncology· @TargetedOnc · X·· 14 hours agoScore70
Body
INTerpath-001 raises exciting questions:
Will improved RFS/DMFS translate into OS benefit?
How does this compare with neoadjuvant immunotherapy?
Can personalized vaccines be manufactured quickly, affordably and at scale?
Innovation must also be deliverable. #ESMO26
59 views · 1 like · 0 reposts · 1 reply
Conference abstracts
LBA1matched by Presidential Symposium I
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.orgReplies in this thread
- WaSaBi@dtabait
@TargetedOnc Not enough events to determine OS.
Source: Targeted Oncology · x.com